Cited 0 times in

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY

Authors
 Yoon-Koo Kang  ;  Hyung-Don Kim  ;  Jeong Hwan Yook  ;  Young-Kyu Park  ;  Jong Seok Lee  ;  Young-Woo Kim  ;  Jin Young Kim  ;  Min-Hee Ryu  ;  Sun Young Rha  ;  Ik Joo Chung  ;  In-Ho Kim  ;  Sang Cheul Oh  ;  Young Soo Park  ;  Jae-Ho Cheong  ;  Oh Jeong  ;  Mi Hwa Heo  ;  Hark Kyun Kim  ;  ChoHyun Park  ;  Chang Hak Yoo  ;  Seok Yun Kang  ;  Dae Young Zang  ;  You Jin Jang  ;  Ji Young Sul  ;  Jong Gwang Kim  ;  Beom Su Kim  ;  Seung-Hoon Beom  ;  Jun-Eul Hwang  ;  Seung Wan Ryu  ;  Myeong-Cherl Kook  ;  Baek-Yeol Ryoo  ;  Hyunki Kim  ;  Moon-Won Yoo  ;  Nam Su Lee  ;  Sang Ho Lee  ;  Sung Hoon Noh 
Citation
 JOURNAL OF CLINICAL ONCOLOGY, Vol.42(25) : 2961-2965, 2024-09 
Journal Title
JOURNAL OF CLINICAL ONCOLOGY
ISSN
 0732-183X 
Issue Date
2024-09
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols* / therapeutic use ; Chemotherapy, Adjuvant ; Docetaxel* / administration & dosage ; Docetaxel* / therapeutic use ; Drug Combinations* ; Female ; Gastrectomy ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy* / mortality ; Oxaliplatin* / administration & dosage ; Oxaliplatin* / therapeutic use ; Oxonic Acid* / administration & dosage ; Oxonic Acid* / therapeutic use ; Stomach Neoplasms* / drug therapy ; Stomach Neoplasms* / mortality ; Stomach Neoplasms* / pathology ; Tegafur* / administration & dosage ; Tegafur* / therapeutic use
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The phase III PRODIGY study demonstrated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improved progression-free survival (PFS) compared with surgery followed by adjuvant S-1 (SC) for patients with resectable locally advanced gastric cancer (LAGC) with clinical T2-3N+ or T4Nany disease. The primary end point was PFS. Overall survival (OS) was the secondary end point. We herein report the long-term follow-up outcomes, including OS, from this trial. A total of 238 and 246 patients were randomly assigned to the CSC and SC arms, respectively, and were treated (full analysis set). As of the data cutoff (September 2022), the median follow-up duration of the surviving patients was 99.5 months. Compared with SC, CSC significantly increased the OS (adjusted hazard ratio [HR], 0.72; stratified log-rank P = .027) with an 8-year OS rate of 63.0% and 55.1% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (HR, 0.70; stratified log-rank P = .016). In conclusion, neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, prolonged the OS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1. It should be considered one of the standard treatment options for patients with LAGC in Asia
Full Text
https://ascopubs.org/doi/10.1200/JCO.23.02167
DOI
10.1200/JCO.23.02167
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyunki(김현기) ORCID logo https://orcid.org/0000-0003-2292-5584
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Beom, Seung Hoon(범승훈) ORCID logo https://orcid.org/0000-0001-7036-3753
Cheong, Jae Ho(정재호) ORCID logo https://orcid.org/0000-0002-1703-1781
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/201809
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links